Disseminated progression of glioblastoma after treatment with bevacizumab.

ABSTRACT:

Objectives

Reports of glioblastoma (GBM) progression following treatment with bevacizumab indicate that a subset of patients develop disseminated, often minimally enhancing tumors that differ from the typical pattern of focal recurrence. We have reviewed our institutional experience with bevacizumab for GBM to evaluate the prognostic factors and outcomes of patients with disseminated progression.

Patients and methods

Medical records of patients treated for GBM at the University of California San Francisco from 2005 to 2009 were reviewed. Patients receiving bevacizumab for focal disease were evaluated and imaging was reviewed to identify patients who progressed in a disseminated pattern. Tumor and treatment factors were compared between focal and disseminated progressors to i

SUBMITTER: Bloch O 

PROVIDER: S-EPMC5565209 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature